Search

Your search keyword '"Arabi, Mariam"' showing total 289 results
Start Over Author "Arabi, Mariam"
289 results on '"Arabi, Mariam"'

1. Tetralogy of Fallot With Absent Pulmonary Valve Syndrome: The Experience of a Tertiary Care Center in a Developing Country.

Author

Farhat, Aziz, Charanek, Sujud, Zareef, Rana, El‐Rassi, Issam, Bitar, Fadi, and Arabi, Mariam

Subjects
ACADEMIC medical centers, PULMONARY valve, TREATMENT effectiveness, TERTIARY care, RETROSPECTIVE studies, PRENATAL diagnosis, DIGEORGE syndrome, SYMPTOM burden, TETRALOGY of Fallot, AGE factors in disease, SURGICAL complications, DISEASES, ELECTROCARDIOGRAPHY, MEDICAL records, ACQUISITION of data, SURVIVAL analysis (Biometry), GENETIC testing, PATIENT aftercare, SYMPTOMS
Abstract

Background: Tetralogy of Fallot with an absent pulmonary valve is a very rare variant of tetralogy. It is characterized by absent valve tissue, severe pulmonary regurgitation, and secondary aneurysmal dilatation of the pulmonary arteries. Aim: In this study, we aim to investigate the clinical presentations, management strategies, and outcomes of patients with tetralogy of Fallot and absent pulmonary valve. Methodology: We retrospectively reviewed the charts of all patients who presented to the American University of Beirut Medical Center between January 2010 and December 2020 and who were diagnosed with this anomaly. Results: A total of 300 cases of tetralogy of Fallot were identified, of which 18 patients had absent pulmonary valves. They were followed up for an average of 8.2 years. Prenatal diagnoses were made in four patients, while 13 patients were identified in the neonatal period, with an average age of 4.5 days. Genetic testing confirmed DiGeorge syndrome in one patient. Five patients underwent surgical intervention in the neonatal period, while the remaining patients were operated on during their early childhood. While overall there were no surgical mortalities nor any need for reinterventions, a variety of morbidities were encountered. Conclusion: This study provides an overview of this rare anomaly and its management in a developing country. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Cardiac biomarkers in COVID-19: what did we learn?

Author

Srour, Lara, Ismail, Jaafar, Zareef, Rana, and Arabi, Mariam

Abstract

AbstractObjectives:COVID-19, caused by the SARS-CoV-2 virus, has generated a global pandemic with a wide range of clinical manifestations. Cardiovascular complications are frequently observed in individuals with COVID-19, particularly those with preexisting cardiovascular risk factors or diseases. Cardiac biomarkers, including troponin, natriuretic peptides, and inflammatory markers, play a vital role in risk stratification, diagnosis, monitoring, and prognosis in COVID-19 patients. These biomarkers provide valuable insights into cardiac injury, myocardial stress, inflammation, and the prediction of adverse cardiovascular outcomes. This review aims to provide better understanding of how Cardiac biomarkers correlate to clinical manifestation of COVID-19.Methods:We retrieved studies from PubMed, Medline, and Google Scholars that included results on cardiac biomarkers in COVID-19. Total of 14 studies were reviewed.Results:8 studies showed evidence of poor progression of the disease when there is increased troponin. 6 studies out of the 14 mentioned in this review showed positive correlation between mortality and elevation in cardiac biomarkers. This shows the significance of cardiac biomarkers in predicting the mortality in patients with COVID-19.Conclusion:It was shown that elevated cardiac biomarkers were associated significantly to poor outcome of covid-19 infection. The outcomes that were linked to increased cardiac biomarkers included increased length of hospitalization, need of life sustaining treatment, myocarditis, invasive and non-invasive respiratory support, and even death were linked to elevated cardiac biomarkers levels.

Published
2024
Full Text
View/download PDF

17. Newborn Pulse Oximetry Screening for Detecting Congenital Heart Disease: Experience at a Tertiary Care Center.

Author

Bulbul, Ziad R., Younis, Nour K., Malaeb, Farah, Hussein, Haytham Bou, Arabi, Mariam, and Bitar, Fadi

Subjects
CONGENITAL heart disease, PULSE oximetry, MEDICAL screening, TERTIARY care, FETAL echocardiography
Abstract

Background. Congenital heart disease (CHD) remains the number one birth defect worldwide. Pulse oximetry screening (POS) is a widely used CHD screening modality effective in detecting critical lesions. This study is aimed at assessing the accuracy and cost-effectiveness of POS in a cohort of term well-babies admitted to a regular nursery in a tertiary care center. Methods. We reviewed the charts of term babies admitted to our regular nursery over a period of one year. The results of POS and the findings of echocardiography were collected. Similarly, we explored the records of our fetal echocardiography program to identify the fetuses screened for CHD during the same period. Results. 900 term babies were born and admitted to newborn nursery at our center, and 69 fetuses were evaluated by our fetal cardiology team during the study period. None of our term babies had a positive POS at birth or 24 hours of age. However, 56 babies had a cardiac echo before hospital discharge due to suspicious findings on physical examination or a family history of CHD. A simple noncritical CHD was noted in 10 of them. Additionally, 53 babies underwent echocardiography within the first five years of life; a simple CHD was noted in 6 of them. In parallel, 21 of our fetuses were found to have CHD: 16 simple CHD and 5 critical CHD (CCHD). Conclusion. Despite its cost-effectiveness and efficacy in screening for CCHD, POS is suboptimal for detecting simple CHD. In the absence of a proper prenatal screening and fetal echocardiography program, POS remains a cost-effective modality for detecting CCHD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. The Muscle-Bound Heart

Author

Refaat, Marwan M., Fahed, Akl C., Hassanieh, Sylvana, Hotait, Mostafa, Arabi, Mariam, Skouri, Hadi, Seidman, Jonathan G., Seidman, Christine E., Bitar, Fadi F., and Nemer, Georges

Published
2016
Full Text
View/download PDF

26. Multisystem inflammatory syndrome in children (MIS-C) and “Near MIS-C”: A continuum?

Author

Khafaja, Sarah, primary, Youssef, Nour, additional, El Zein, Zeinab, additional, Boutros, Celina F., additional, Bou Karroum, Samer, additional, Abdel-Halim, Nour, additional, Salameh, Rim, additional, Hodroj, Daniella, additional, El Meski, Nour, additional, Nasrallah, Oussama, additional, Bidikian, Aram, additional, Bou Saba, Ghassan, additional, Arabi, Mariam T., additional, Hanna-Wakim, Rima, additional, and Dbaibo, Ghassan S., additional

Published
2023
Full Text
View/download PDF

34. Aspirin in COVID-19: Pros and Cons

Author

Zareef, Rana, primary, Diab, Marwa, additional, Al Saleh, Tala, additional, Makarem, Adham, additional, Younis, Nour K., additional, Bitar, Fadi, additional, and Arabi, Mariam, additional

Published
2022
Full Text
View/download PDF

35. COVID-19: potential therapeutics for pediatric patients

Author

Younis, Nour K., Zareef, Rana O., Fakhri, Ghina, Bitar, Fadi, Eid, Ali H., and Arabi, Mariam

Subjects
Alanine, Ivermectin, SARS-CoV-2, Pediatric patients, Anti-Inflammatory Agents, COVID-19, Antibodies, Monoclonal, Paediatrics, Review, Therapeutics, Azithromycin, Antibodies, Monoclonal, Humanized, Antiviral Agents, Adenosine Monophosphate, Dexamethasone, Lopinavir, COVID-19 Drug Treatment, Oseltamivir, Pharmacology and pharmaceutical sciences, Spike Glycoprotein, Coronavirus, Humans, Child, Hydroxychloroquine
Abstract

The global spread of COVID-19 has imparted significant economic, medical, and social burdens. Like adults, children are affected by this pandemic. However, milder clinical symptoms are often experienced by them. Only a minimal proportion of the affected patients may develop severe and complicated COVID-19. Supportive treatment is recommended in all patients. Antiviral and immunomodulatory medications are spared for hospitalized children with respiratory distress or severe to critical disease. Up till now, remdesivir is the only USFDA-approved anti-COVID-19 medication indicated in the majority of symptomatic patients with moderate to severe disease. Dexamethasone is solely recommended in patients with respiratory distress maintained on oxygen or ventilatory support. The use of these medications in pediatric patients is founded on evidence deriving from adult studies. No randomized controlled trials (RCTs) involving pediatric COVID-19 patients have assessed these medications’ efficacy and safety, among others. Similarly, three novel monoclonal anti-SARS-CoV-2 spike protein antibodies, bamlanivimab, casirivimab and imdevimab, have been recently authorized by the USFDA. Nonetheless, their efficacy has not been demonstrated by multiple RCTs. In this review, we aim to dissect the various potential therapeutics used in children with COVID-19. We aspire to provide a comprehensive review of the available evidence and display the mechanisms of action and the pharmacokinetic properties of the studied therapeutics. Our review offers an efficient and practical guide for treating children with COVID-19.Other Information Published in: Pharmacological Reports License: https://creativecommons.org/licenses/by/4.0See article on publisher's website: http://dx.doi.org/10.1007/s43440-021-00316-1

Published
2022
Full Text
View/download PDF

42. Acute Kidney Injury Post-cardiac Surgery in Infants and Children: A Single-Center Experience in a Developing Country

Author

Aoun, Bilal, primary, Daher, Ghadi Abu, additional, Daou, Karim N., additional, Sanjad, Sami, additional, Tamim, Hani, additional, El Rassi, Issam, additional, Arabi, Mariam, additional, Sharara, Rana, additional, Bitar, Fadi, additional, Assy, Jana, additional, Bulbul, Ziad, additional, Degheili, Jad A., additional, and Majdalani, Marianne, additional

Published
2021
Full Text
View/download PDF

47. ARRHYTHMIAS IN NEONATES AND INFANTS AT A TERTIARY CARE CENTER

Author

Abohelwa, Mostafa, primary, Refaat, Marwan, additional, Ahmed, Mohamed Atia, additional, Ibrahim, Maryam, additional, Elgehiny, Amr, additional, Zakka, Patrick, additional, Rassi, Isam El, additional, Bitar, Fadi, additional, Bulbul, Ziad, additional, and Arabi, Mariam, additional

Published
2021
Full Text
View/download PDF

48. Transcatheter occlusion of a hepatic vein-to-left atrium fistula: Should we close venovenous collateral vessels following Fontan operation?

Author

El-Khouri, Maya, Arabi, Mariam, El Rassi, Issam, Bulbiil, Ziad, Sawaya, Fadi, and Bitar, Fadi

Subjects
*CARDIAC catheterization, *FISTULA, *HEPATIC veins, *TREATMENT effectiveness, *CARDIOPULMONARY bypass, *VASCULAR diseases, *HEMODYNAMICS, *LEFT heart atrium, *HYPOXEMIA
Abstract

Right-to-left shunt due to abnormal systemic venous drainage to the left heart is among the causes of hypoxemia following Fontan operation. There are conflicting data regarding the closure of the venovenous collaterals (VVCs) post-Fontan, showing decreased survival in older patients. In a child with visceral heterotaxy, we describe a rare fistula draining a right-sided hepatic vein into hepatic venous plexus and a right-sided pulmonary venous atrium. The patient presented with severe hypoxemia post-Fontan and underwent fistula occlusion with AMPLATZER™ Vascular Plug II, successfully improving hemodynamic status with resolution of the hypoxemia. Younger patients with cyanosis due to WCs may benefit from percutaneous occlusion post-Fontan. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Arrhythmias in Neonates and Infants at a Tertiary Care Center

Author

Refaat, Marwan, primary, Abohelwa, Mostafa M, additional, Ahmed, Mohamed, additional, Elgehiny, Amr, additional, Ibrahim, Maryam, additional, Zakka, Patrick, additional, El Rassi, Isam, additional, Bulbul, Ziad, additional, Bitar, Fadi, additional, and Arabi, Mariam, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results